27 stories mentioning RMDUpdated 6d ago
Every FINWIRES story that references RMD, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
ResMed (RMD) has an average rating of overweight and mean price target of $286.27, according to analysts polled by FactSet.Price: $202.74, Change: $-11.07, Percent Change: -5.18%
ResMed (RMD) has an average rating of overweight and mean price target of $286.27, according to analysts polled by FactSet.Price: $204.27, Change: $-9.54, Percent Change: -4.46%
ResMed (RMD) has an average rating of overweight and mean price target of $286.27 according to analysts polled by FactSet.Price: $201.18, Change: $-12.57, Percent Change: -5.88%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ResMed delivered mixed Q3 FY 26 results with revenue growing 11% to $1.43B, $20M below expectations, while non-GAAP EPS of $2.86 rose 21%, beating consensus by $0.06. Geographic performance showed broad strength with U.S./Canada/Latin America up 9% and Europe/Asia expanding 16%, while masks/accessories outpaced devices with 16% vs 9% growth. The standout highlight was gross margin expansion of 290 bps to 62.2% driven by manufacturing efficiencies and component cost improvements, demonstrating operational excellence in our view. The company continues advancing its digital health strategy with new product launches including the AirTouch F30i mask and plans for a 2027 Indiana distribution center. We expect the recently completed VirtuOx acquisition to strengthen diagnostic capabilities within ResMed's digital health ecosystem across 140+ countries, positioning the company well for continued growth in the expanding sleep and respiratory care market.
ResMed (RMD) has an average rating of overweight and mean price target of $298.71, according to analysts polled by FactSet.Price: $220.36, Change: $+0.51, Percent Change: +0.23%
ResMed (RMD) has an average rating of overweight and mean price target of $304.80, according to analysts polled by FactSet.Price: $228.68, Change: $-2.01, Percent Change: -0.87%
ResMed (RMD) has an average rating of overweight and mean price target of $305.30, according to analysts polled by FactSet.Price: $228.56, Change: $-0.31, Percent Change: -0.14%
Showing 21-27 of 27
